Dermatologist Evaluation + Metabolic Screening
HbA1c, fasting insulin, lipid panel, liver enzymes, thyroid panel, vitamin D
Physician-led metabolic-health programme using lifestyle therapy as the foundation and GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) where clinically indicated for BMI ≥27 with co-morbidity or BMI ≥30. Indian BMI thresholds applied per ICMR: Overweight ≥23, Obese ≥25 — substantially lower than WHO defaults. Pre-treatment labs (fasting glucose, HbA1c, lipid panel, TSH, LFT, RFT), monthly follow-up, structured nutrition and resistance-exercise plan in parallel.
The ICMR 2009 expert consensus on Indian BMI thresholds set Overweight at ≥23 and Obese at ≥25 — substantially lower than WHO defaults of 25 / 30 — based on Indian-cohort data showing cardio-metabolic risk equivalent to Europeans at lower BMI. Using WHO thresholds in Indian practice misses the early-intervention window by a decade. Our Kollam programme uses Indian thresholds throughout, adds waist circumference (Indian male >90 cm, female >80 cm) as an equally weighted risk marker, and screens for the metabolic-syndrome cluster (HTN, dyslipidaemia, fasting glucose) at every visit. GLP-1 receptor agonists are prescribed only on label for BMI ≥27 with co-morbidity or BMI ≥30, with monthly follow-up.
DermaVue Kollam SuperHuman Programme provides dermatologist-supervised metabolic health and weight management combining GLP-1 receptor agonist therapy (where clinically indicated and screened), Kerala-adapted nutrition plans and longitudinal cardiometabolic monitoring. A 2025 New England Journal of Medicine study confirmed tirzepatide produces 16.5 percent body weight reduction at one year versus 14.1 percent for semaglutide, validated in real-world Indian cohorts through the SHAPE study (2026). The programme applies Indian-specific BMI thresholds (overweight 23, obese 25) per ICMR guidance rather than WHO Western thresholds. DermaVue is a dermatologist-owned network rated 4.9 stars in Kollam across 370+ patient reviews and serves patients from Chinnakada, Kadappakkada, Paravur, Kottarakkara and Punalur.
HbA1c, fasting insulin, lipid panel, liver enzymes, thyroid panel, vitamin D
semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro) when clinically indicated and contraindications screened
bioimpedance spectroscopy to monitor muscle preservation alongside fat reduction
registered-dietitian plans that retain kanji, appam, fish curry and traditional meals with modified portions
insulin sensitivity focus for women with PCOS and weight gain
combined glycaemic and weight optimisation with hypoglycaemia monitoring
muscle-preserving exercise guidance with minimum 1.2 g protein per kg body weight per day
monthly dermatologist review, dose titration, side-effect management and habit reinforcement
gradual GLP-1 dose reduction once metabolic targets and sustainable habits are established
blood pressure, lipid and HbA1c tracking aligned with longevity outcomes
Dr Jayalekshmi J and Dr Arunima A both hold the MD DVL postgraduate qualification and own every file together. Continuity of care is the default, not a tagline.
Dermatology, Cosmetology, Medical Dermatology
Dermatology, Dermatosurgery, Lasers & Aesthetic Procedures
Direct line to the team WhatsApp +91 80868 60465 →
Initial consultation is Rs.300. Programme tiers and GLP-1 medication options are discussed transparently after metabolic screening. Brand semaglutide starts around Rs.5,660 per month at starter dose and varies with dose and brand. Indian generic semaglutide became available after the March 2026 patent expiry and is expected to reduce costs. Your dermatologist outlines all options.
GLP-1 receptor agonists have extensive safety data from large clinical trials. Side effects are primarily gastrointestinal (nausea, reduced appetite) and typically mild with gradual dose titration. Your dermatologist screens for contraindications including medullary thyroid cancer history, MEN-2, pancreatitis and gallbladder disease before prescribing, then monitors quarterly.
Most patients notice reduced appetite within the first week and improved fasting glucose within 4-6 weeks. Visceral fat (around the organs) often reduces faster than subcutaneous fat, so cardiometabolic risk markers can improve before the scale reflects the full change. Sustained body weight reduction continues over 4-12 months under dermatologist supervision.
A 2025 NEJM study showed tirzepatide (Mounjaro) achieves around 16.5 percent body weight reduction at one year versus 14.1 percent for semaglutide (Ozempic). However, the best choice depends on your individual metabolic profile, side-effect tolerance, contraindications and budget. Your dermatologist recommends based on your specific situation, not on weight loss numbers alone.
No. Most patients use GLP-1 medications for 12-18 months while building sustainable nutrition and activity habits. The programme includes a structured taper plan once metabolic targets are reached. Some patients with type 2 diabetes may continue at a low maintenance dose for longer-term glycaemic and cardiometabolic benefit, under dermatologist review.
Our registered dietitian designs Kerala-adapted plans that work within your existing food preferences. White rice portions reduce, protein from fish and legumes increases, and tapioca frequency decreases. Kanji, appam and Kollam-style fish curry can be modified rather than eliminated. Minimum 1.2 g protein per kg body weight per day to preserve muscle mass.
GLP-1 medications can be particularly helpful for PCOS-related weight gain because they improve insulin sensitivity, which is a core metabolic driver of PCOS. Improved insulin function often results in better hormone regulation, more regular cycles and reduced androgen-related symptoms alongside weight management. Our dermatologists in Kollam also address PCOS-related skin concerns such as acne and hirsutism.
Exercise preserves muscle and improves metabolic health, but research consistently shows it produces modest body fat reduction when used alone (typically 2-3 percent). For significant visceral fat reduction and sustained metabolic improvement, structured nutrition and, where indicated, medication produce substantially better outcomes than exercise in isolation.
Yes. Type 2 diabetes is a primary indication for GLP-1 medications. Semaglutide and tirzepatide improve both weight and blood sugar control simultaneously and have demonstrated cardiometabolic benefits. Patients already on diabetes medication need monitoring for hypoglycaemia, so your dermatologist adjusts all medications together.
Pregnancy and lactation, personal or family history of medullary thyroid carcinoma, MEN-2 syndrome, history of pancreatitis, type 1 diabetes, active gallbladder disease, severe gastroparesis and known hypersensitivity to semaglutide or tirzepatide. Patients with diabetic retinopathy need careful HbA1c reduction planning. Dermatologist screening at first consultation rules these out.
A dermatologist-supervised metabolic health programme combining four pillars: dermatologist evaluation with metabolic screening, GLP-1 receptor agonist medication where indicated, Kerala-adapted nutrition guidance, and muscle-preserving activity protocols with longitudinal cardiometabolic monitoring. The programme runs 12-18 months with regular dermatologist check-ins and body composition tracking, and is framed around long-term metabolic health and longevity rather than cosmetic weight loss.
WhatsApp DermaVue Kollam at +91 8086860465 or call directly. The clinic is at UMK Arcade, Vellayittambalam, Kavanad. Patients often combine the metabolic health programme with skin rejuvenation treatments such as Botox in Kollam. Initial consultation includes comprehensive assessment and personalised planning. Consultation fee: Rs.300.
₹300 consultation · same-day slots available · Kavanad clinic open Mon–Sat 10 AM – 7 PM, Sun closed.